Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
抗生素和抗病毒
/
抗感染
结构
/
头孢烯类
Antibacterial
/ Cefoperazone/头孢哌酮

Cefoperazone/头孢哌酮 {[allProObj[0].p_purity_real_show]}

货号：A194605

Cefoperazone是一种第三代β-内酰胺类头孢菌素抗生素，可以与细菌细胞壁内的特定青霉素结合蛋白（PBPs）结合，抑制细菌细胞壁合成的第三个和最后一个阶段。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Cefoperazone/头孢哌酮 化学结构 CAS号：62893-19-0
Cefoperazone/头孢哌酮 化学结构
CAS号：62893-19-0
Cefoperazone/头孢哌酮 3D分子结构
CAS号：62893-19-0
Cefoperazone/头孢哌酮 化学结构 CAS号：62893-19-0
Cefoperazone/头孢哌酮 3D分子结构 CAS号：62893-19-0
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Cefoperazone/头孢哌酮 纯度/质量文件 产品仅供科研

货号：A194605 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >

Cefoperazone/头孢哌酮 生物活性

描述 Cefoperazone is a third‐generation cephalosporin and is one of a small number of cephalosporins that are effective in treating Pseudomonas bacterial infections (MIC50 25 μg/mL). The hydrolysis product of cefoperazone was noncovalently bound in the active site of PBP3. This may be important in the design of new noncovalent PBP3 inhibitors[3]. After intramuscular injection of 2 g of cefoperazone, the mean peak serum level was 111 microgram/ml at 1.5 hours. At 12 hours after dosing, mean serum levels were still 2 to 4 microgram/ml. Cefoperazone was 90% bound to serum proteins[4]. Both the inhibitory potency of the cephalosporins for Mrp2-mediated (multidrug resistance-associated protein) transport and the uptake of cephalosporins by Mrp2-expressing vesicles were molecular weight-dependent[5].

Cefoperazone/头孢哌酮 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Male C57BL/6 mice Antibiotic-induced susceptible gut microbiota model Drinking water 0.5 mg/mL 5 consecutive days To investigate whether cefoperazone-treated mice could clear Clostridioides difficile infection after fecal community transplant (FCT) pretreatment. Results showed that cefoperazone-treated mice became colonized by C. difficile, but the FCT enabled clearance of C. difficile. mBio. 2022 Aug 30;13(4):e0136422
New Zealand White rabbits Enterobacter aerogenes endocarditis model Intramuscular 60 mg/kg Every 6 hours for 5 or 10 days To compare the efficacy of cefoperazone with enoxacin in treating Enterobacter aerogenes endocarditis. Cefoperazone did not differ significantly from enoxacin at 25 mg/kg in reducing bacterial titers but was less effective than enoxacin at 100 mg/kg. Antimicrob Agents Chemother. 1985 May;27(5):708-11
C57BL/6 mice Clostridium difficile infection model Drinking water administration 0.5 g/L 5 consecutive days To study the effect of cefoperazone pretreatment on Clostridium difficile infection, results showed that cefoperazone treatment significantly reduced colonic bacterial diversity and promoted C. difficile colonization Gut Microbes. 2014 Jul 1;5(4):476-84
C57BL/6 mice C. difficile infection model Drinking water 0.5 mg/mL Once daily for 5 days Establish a C. difficile infection model, results showed that cefoperazone-treated mice successfully established the infection model Virulence. 2025 Dec;16(1):2503432
BALB/c mice Systemic infection model and thigh infection model Intravenous injection 200 mg/kg Single dose, observed for 7 days To evaluate the effect of valine and cefoperazone-sulbactam combination in mouse infection models. Results showed that the combination significantly reduced bacterial load in the liver, spleen, and kidney, and improved mouse survival. mSystems. 2025 Jan 21;10(1):e0124424
C57BL/6 mice Clostridium difficile infection model Drinking water 0.5 mg/ml Daily for 10 days To assess differential virulence of C. difficile strains Gut Microbes. 2011 Nov-Dec;2(6):326-34

Cefoperazone/头孢哌酮 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02099240 Osteomyelitis Early Phase 1 Recruiting September 2019 United States, Kentucky ... 展开 >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD 收起 <<
NCT03003273 Neutropenia, Febrile ... 展开 >> Pediatric Cancer 收起 << Phase 3 Recruiting December 2018 India ... 展开 >> Department of Medical Oncology, AIIMS Recruiting New Delhi, India, 110029 Contact: Sameer Bakhshi, MD    011-29575237    sambakh@hotmail.com 收起 <<
NCT01601093 Respiratory Tract Infections ... 展开 >> Urinary Tract Infections 收起 << Phase 2 Unknown November 2013 China, Jiangsu ... 展开 >> the First Affiliated Hospital With Medical University Recruiting Nanjing, Jiangsu, China Contact: hong wh wang, doctor    025-83714511 ext 6360       Sub-Investigator: mao hm huang, doctor 收起 <<

Cefoperazone/头孢哌酮 参考文献

[1]Kato Y, Takahara S, et al. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab Dispos. 2008 Jun;36(6):1088-96.

[2]Craig WA, Gerber AU. Pharmacokinetics of cefoperazone: a review. Drugs. 1981;22 Suppl 1:35-45.

[3]Ren J, Nettleship JE, Males A, Stuart DI, Owens RJ. Crystal structures of penicillin-binding protein 3 in complexes with azlocillin and cefoperazone in both acylated and deacylated forms. FEBS Lett. 2016 Jan;590(2):288-97.

[4]Craig WA, Gerber AU. Pharmacokinetics of cefoperazone: a review. Drugs. 1981;22 Suppl 1:35-45.

[5]Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, Tsuji A. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab Dispos. 2008 Jun;36(6):1088-96.

Cefoperazone/头孢哌酮 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.55mL

0.31mL

0.15mL

7.74mL

1.55mL

0.77mL

15.49mL

3.10mL

1.55mL

Cefoperazone/头孢哌酮 技术信息

CAS号62893-19-0
分子式C25H27N9O8S2
分子量 645.67
SMILES Code O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@H](NC([C@H](NC(N4C(C(N(CC)CC4)=O)=O)=O)C5=CC=C(O)C=C5)=O)C1=O)O
MDL No. MFCD00865067
别名
运输蓝冰
InChI Key GCFBRXLSHGKWDP-XCGNWRKASA-N
Pubchem ID 44187
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, 2-8°C
溶解方案

DMSO: 105 mg/mL(162.62 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
方案 二
方案 三

Tags: Cefoperazone | 62893-19-0 | Bacterial Inhibitor | Anti-infection | Bacterial | Antibiotic | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Cefoperazone/头孢哌酮 纯度/质量文件 | Cefoperazone/头孢哌酮 生物活性 | Cefoperazone/头孢哌酮 临床数据 | Cefoperazone/头孢哌酮 参考文献 | Cefoperazone/头孢哌酮 实验方案 | Cefoperazone/头孢哌酮 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z